Stifel Nicolaus Has Lowered Expectations for Affimed (NASDAQ:AFMD) Stock Price

Affimed (NASDAQ:AFMD) had its target price trimmed by Stifel Nicolaus from $5.00 to $4.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

AFMD has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Monday, September 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Affimed Stock Down 9.2 %

Shares of AFMD opened at $3.16 on Friday. Affimed has a 52 week low of $2.92 and a 52 week high of $8.95. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13. The stock has a fifty day moving average of $3.49 and a 200-day moving average of $4.51.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative net margin of 7,836.26% and a negative return on equity of 165.35%. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. As a group, research analysts forecast that Affimed will post -4.25 EPS for the current fiscal year.

Institutional Trading of Affimed

A number of large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Affimed during the 3rd quarter worth about $44,000. Point72 Asset Management L.P. grew its holdings in Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares during the period. FMR LLC grew its stake in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the period. Intellectus Partners LLC grew its stake in shares of Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the period. Finally, Choreo LLC acquired a new stake in shares of Affimed in the 2nd quarter valued at about $54,000. 30.82% of the stock is currently owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.